Parnax Lab is a pharmaceutical contract manufacturer that produces liquid formulations, ointments, and cosmetics for domestic and international markets. The company earns revenue by manufacturing products for other pharmaceutical brands and selling its own formulations, primarily in developing regions.
The company operates in a highly fragmented contract manufacturing space with low barriers to entry, evidenced by thin net margins of 3.3%. While they claim a niche in veterinary and liquid dosages, the lack of high ROIC or durable pricing power suggests they are largely a price-taker in a commodity-like service industry.
Earnings are primarily reinvested into the business or used to provide inter-corporate loans to its subsidiary, Naxpar Pharma. The company has refrained from paying dividends, prioritizing liquidity and internal funding for its subsidiary's operations.
The investment collapsed as the thin 3.3% margins were completely erased by rising raw material costs and increased competition in the commodity contract manufacturing space. The sudden 2024 leadership vacuum proved fatal as the lack of a clear succession plan led to operational drift and the mismanagement of inter-corporate loans. Ultimately, the unresolved legal disputes over land titles and the failure to formalize property transfers post-merger resulted in asset impairment and a loss of creditor confidence, leaving the company unable to service its debt with such meager interest coverage.
RichFakir rates Parnax Lab Ltd's business quality as poor — 36/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Parnax Lab Ltd is trading about 18% below our estimate of fair value; we rate its price fair. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Parnax Lab Ltd is: Not rated. A poor business at a fair price — it does not make our shortlist right now.
RichFakir's educational estimate of Parnax Lab Ltd's fair value is about ₹131 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →